Peoniflorin Preconditioning Protects Against Myocardial Ischemia/Reperfusion Injury Through Inhibiting Myocardial Apoptosis: RISK Pathway Involved

被引:0
作者
Hongen Ma
Jiping Hao
Huihui Liu
Jia Yin
Mingmin Qiang
Meilin Liu
Shaohui He
Di Zeng
Xiongtao Liu
Cheng Lian
Yuqin Gao
机构
[1] Ninth Affiliated Hospital of Medical College of Xi’an Jiaotong University,Department of Cardiology
[2] Medical College of Yan’an University,Department of Cardiology
[3] Tangdu Hospital,undefined
[4] Fourth Military Medical University,undefined
来源
Applied Biochemistry and Biotechnology | 2022年 / 194卷
关键词
Peoniflorin; RISK pathway; Ischemia/reperfusion injury; Myocardial apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
Preconditioning with Peoniflorin, a component of traditional Chinese prescriptions, was proposed to be a potential strategy for cardioprotection against ischemia/reperfusion (I/R) injury. However, the cardioprotective effect of Peoniflorin preconditioning has not been thoroughly confirmed, and the underlying mechanism remains unclear. Here, we examined the cardioprotective effect and its mechanism of Peoniflorin preconditioning against myocardial I/R injury. Rats were subjected to 30 min of transient ischemia followed by 2 h of reperfusion with or without Peoniflorin (100 mg/kg) prior to reperfusion. Peoniflorin preconditioning significantly limited myocardial infarct size and reperfusion arrhythmias, as well as obviously attenuated the histomorphological and micromorphological damages induced by I/R injury. The reduced myocardial injury was also associated with the anti-apoptotic effect of Peoniflorin, as evidence by decreased TUNEL-positive cells, upregulation of BCL-2 expression, and downregulation of Bax and caspase-3 expression. In an effort to evaluate the mechanism responsible for the observed cardioprotective and anti-apoptotic effect, Western blot of phosphorylated protein was performed after 20 min of reperfusion. Results showed that Peoniflorin preconditioning activated both the Akt and ERK1/2 arm of the reperfusion injury salvage kinase (RISK) pathway. To further confirm this mechanism, the PI3K signaling inhibitor LY294002 and ERK1/2 signaling inhibitor PD98059 were administered in vivo. The cardioprotective and anti-apoptotic effects of Peoniflorin preconditioning were diminished but not abolished by pretreatment with LY294002 or PD98059. Taken together, these results indicate that Peoniflorin preconditioning protects the myocardial against I/R injury and inhibits myocardial apoptosis via the activation of the RISK pathway, highlighting the potential therapeutic effects of Peoniflorin on reducing myocardial I/R injury.
引用
收藏
页码:1149 / 1165
页数:16
相关论文
共 231 条
  • [1] Hillis LD(2006)Myocardial infarction and the open-artery hypothesis New England Journal of Medicine 355 2475-2477
  • [2] Lange RA(2007)Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction Heart Failure Reviews 12 207-216
  • [3] Rodriguez-Sinovas A(2007)Preconditioning and postconditioning: United at reperfusion Pharmacology and Therapeutics 116 173-191
  • [4] Abdallah Y(2005)Postconditioning the human heart Circulation 112 2143-2148
  • [5] Piper HM(2015)Remote ischemic conditioning Journal of the American College of Cardiology 65 177-195
  • [6] Garcia-Dorado D(2013)Ischemic postconditioning during primary percutaneous coronary intervention: The effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial Circulation 128 1889-1896
  • [7] Hausenloy DJ(2015)Evolving therapies for myocardial ischemia/reperfusion injury Journal of the American College of Cardiology 65 1454-1471
  • [8] Yellon DM(2015)CAESAR: One step beyond in the construction of a translational bridge for cardioprotection Circulation Research 116 554-556
  • [9] Staat P(2014)Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: A randomized controlled clinical trial International Journal of Cardiology 177 935-941
  • [10] Rioufol G(2015)The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): A new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs Circulation Research 116 572-586